![Charles Pyke](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Network origin in Charles Pyke first degree
Entity | Entity type | Industry | |
---|---|---|---|
OncoTac Pharmaceuticals ApS
![]() OncoTac Pharmaceuticals ApS Pharmaceuticals: MajorHealth Technology OncoTac Pharmaceuticals ApS develops and commercializes therapeutics for the treatment of cancer diseases. The company was founded by Thomas Senderovitz, John Rømer Nielsen, Charles Pyke, Paul Kristjansen, and Søren Pontoppidan and is headquartered in Copenhagen, Denmark.
4
| Extinct | Pharmaceuticals: Major | 4 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Charles Pyke via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
University of Copenhagen | College/University | Graduate Degree Doctorate Degree | |
SEED Capital Management I/S
![]() SEED Capital Management I/S Investment ManagersFinance SEED Capital Management I/S is an Independent Venture Capital firm founded in 2004. The company is headquartered in Copenhagen, Denmark. | Investment Managers | Private Equity Investor | |
Statens Serum Institute | College/University | Doctorate Degree | |
PAREXEL INTERNATIONAL CORPORATION | Miscellaneous Commercial Services | Chief Tech/Sci/R&D Officer | |
Ferring Pharmaceuticals A/S
![]() Ferring Pharmaceuticals A/S Pharmaceuticals: MajorHealth Technology Ferring Pharmaceuticals A/S specializes in the development, production and marketing of pharmaceutical products. It offers products in the fields of urology, infertility, obstetrics, gynecology, gastroenterology and maternal health. The company is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Grünenthal GmbH
![]() Grünenthal GmbH Pharmaceuticals: MajorHealth Technology Grünenthal GmbH engages in the research and development of pharmaceutical products. It specializes in pain, gout, and inflammation. The company was founded by Hermann Wirtz in 1946 and is headquartered in Aachen, Germany. | Pharmaceuticals: Major | Corporate Officer/Principal | |
University of Aarhus | College/University | Graduate Degree | |
SP Sveriges Tekniska Forskningsinstitut AB
![]() SP Sveriges Tekniska Forskningsinstitut AB Miscellaneous Commercial ServicesCommercial Services SP Sveriges Tekniska Forskningsinstitut AB operates as a international research institute. Its business areas include energy, information and communications technology, life science, risk, safety and security, the built environment and transportation. The company was founded in 1920 and is headquartered in Borås, Sweden. | Miscellaneous Commercial Services | Sales & Marketing | |
CanImGuide Therapeutics AB
![]() CanImGuide Therapeutics AB Pharmaceuticals: MajorHealth Technology CanImGuide Therapeutics AB develops cancer therapies. The firm is a biotechnological company that reverses cancer related immunosuppression. It manufactures the proprietary drug P28R, a peptide with two modes of actions. The company was founded on March 21, 2006 and is headquartered in Hollviken, Sweden. | Pharmaceuticals: Major | Director/Board Member | |
Evolva A/S | Director/Board Member | ||
Acesion Pharma ApS
![]() Acesion Pharma ApS Pharmaceuticals: MajorHealth Technology Acesion Pharma ApS develops drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. The firm's technology blocks ion channel with a selective drug molecule constitutes a target for developing treatment of AF. The company was founded by Ulrik Svane S?rensen and Morten Grunnet in 2011 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Director/Board Member | |
Minervax ApS
![]() Minervax ApS Medical SpecialtiesHealth Technology Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark. | Medical Specialties | Director/Board Member | |
ALK-ABELLÓ A/S | Biotechnology | Corporate Officer/Principal | |
Danske Private Equity A/S
![]() Danske Private Equity A/S Investment ManagersFinance Danske Private Equity A/S (DPE) is a private equity fund of funds investment firm founded in 1999. The firm is headquartered in Lyngby. | Investment Managers | Corporate Officer/Principal | |
ACARIX AB | Medical Specialties | Director/Board Member | |
Celltrix AB
![]() Celltrix AB Medical SpecialtiesHealth Technology Celltrix AB manufactures medical devices. It develops novel and injectable dermal filler for reconstructive cosmetic surgery, based on microbeads of cross-linked gelatine. The company was founded in December 2003 by Kjell Gösta Conny Nilsson and is headquartered in Malmö, Sweden. | Medical Specialties | Director/Board Member | |
Contera Pharma ApS
![]() Contera Pharma ApS Pharmaceuticals: MajorHealth Technology Contera Pharma ApS is a holding company that identifies and develops treatments for patients suffering from movement disorders. It develops drug candidates based on a combination of repositioning, combinations, and reformulations. The firm's lead project JM-010 is for treatment of dyskinesia associated with Parkinson's disease. It develops an approach of using a combination therapy to tackle clinically relevant synergistic pathways to obtain therapeutic effects which will generate efficacious therapeutic entities based on robust pre-clinical and clinical evidence. The company was founded by Mikael Søndergaard Thomsen and John Bondo Hansen in 2010 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Director/Board Member | |
Galecto Biotech ApS
![]() Galecto Biotech ApS Pharmaceuticals: MajorHealth Technology Galecto Biotech ApS provides galectin modulators for the treatment of severe diseases, including fibrosis and cancer. Its products include galectin-3 inhibitors, fibrosis and literature. The company was founded by Tariq Sethi, Hans Thalsgard Schambye, Ulf Jorgen Nilsson, and Hakon Leffler in 2011 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Director/Board Member | |
Reapplix A/S
![]() Reapplix A/S Medical DistributorsDistribution Services Reapplix A/S specializes in the biological treatment and management of diabetic foot ulcers. It develops the LeucoPatch device, which is composed of precision molded medical grade plastic components, that facilitates a processing of autologous blood. The company was founded by Niels Erik Holm and Rasmus Lundquist in 2008 and is headquartered in Birkerod, Denmark. | Medical Distributors | Director/Board Member | |
EpiTherapeutics ApS
![]() EpiTherapeutics ApS BiotechnologyHealth Technology EpiTherapeutics ApS is a holding company that develops cancer drugs based on research in the field of epigenetics. Its development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases. The firm's regulation is commonly used for post-translational covalent modifications of histones and other chromatin-remodeling complexes, which determines whether a gene is accessible and hence, expressed or repressed. Its covalent modifications involved in epigenetic regulation include deoxyribonucleic acid methylation, histone acetylation, and histone methylation. The company was founded by Kristian Helin, Paul Andreas Compare Cloos, Jesper Aagaard Christensen, Karl Agger, and Klaus Hansen on September 18, 2008 and is headquartered in Greve, Denmark. | Biotechnology | Director/Board Member | |
Bok Holding A/S
![]() Bok Holding A/S BiotechnologyHealth Technology Bok Holding A/S is a holding company that operates as a biotechnology company that researches and develops cancer treatment solutions. It develops the ZAS platform technology which efficiently enhances the effect of current anti-cancer drugs and reduces toxicity. The firm employs molecular techniques commonly known as molecular breeding or directed enzyme evolution which can activate anti-cancer drugs. The company was founded by Zoran Gojkovic on November 22, 2001 and is headquartered in Gentofte, Denmark. | Biotechnology | Director/Board Member | |
UCB Pharma, Inc.
![]() UCB Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services UCB Pharma, Inc. provides research, development & commercialisation of pharmeceutical and biotechnology products. Its products are Keppra, Xyzal, Atarax, Lortab, Dipentum, and Tussionex. UCB Pharma develops small and large molecule treatments for a variety of diseases and ailemts. The company was founded by Emmanuel Janssen in 1928 and is headquartered in Smyrna, GA. | Miscellaneous Commercial Services | Corporate Officer/Principal |
Statistics
International
Denmark | 19 |
Sweden | 5 |
United States | 3 |
Germany | 2 |
Sectoral
Health Technology | 16 |
Consumer Services | 4 |
Commercial Services | 4 |
Finance | 3 |
Distribution Services | 2 |
Operational
Director/Board Member | 15 |
Corporate Officer/Principal | 10 |
Founder | 3 |
Doctorate Degree | 2 |
Graduate Degree | 2 |
Most connected contacts
Insiders | |
---|---|
Carsten Schou | 20 |
Thomas Senderovitz | 6 |
John Rømer Nielsen | 2 |
Soren Pontoppidan | 2 |
- Stock Market
- Insiders
- Charles Pyke
- Company connections